pIRS2 phosphopeptide-tetanus peptide vaccine

{
  "id": "MLC-T-ONC-016094",
  "term": "pIRS2 phosphopeptide-tetanus peptide vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A vaccine composed of a phosphorylated peptide from the tumor associated antigen insulin receptor substrate-2 (IRS2) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. Upon administration of pIRS2 phosphopeptide-tetanus peptide vaccine, the pIRS2 phosphopeptide may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against phosphopeptide-containing tumor cells. The tetanus peptide serves as an immunoadjuvant and induces a helper T-cell response which may help stimulate an immune response against the pIRS2-expressing melanoma tumor cells. IRS2 is upregulated in a variety of cancer cells.",
  "synonyms": [
    "pIRS2-phosphopeptide plus Tet vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pirs2-phosphopeptide-tetanus-peptide-vaccine/"
}